ATE116540T1 - Teilchenzubereitung mit verzögerter wirkstoffabgabe und deren zubereitungsmethode. - Google Patents

Teilchenzubereitung mit verzögerter wirkstoffabgabe und deren zubereitungsmethode.

Info

Publication number
ATE116540T1
ATE116540T1 AT87114584T AT87114584T ATE116540T1 AT E116540 T1 ATE116540 T1 AT E116540T1 AT 87114584 T AT87114584 T AT 87114584T AT 87114584 T AT87114584 T AT 87114584T AT E116540 T1 ATE116540 T1 AT E116540T1
Authority
AT
Austria
Prior art keywords
preparation
active ingredients
delayed release
active agent
pharmacologically active
Prior art date
Application number
AT87114584T
Other languages
English (en)
Inventor
Minoru Machida
Masayuki Arakawa
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE116540T1 publication Critical patent/ATE116540T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT87114584T 1986-10-07 1987-10-06 Teilchenzubereitung mit verzögerter wirkstoffabgabe und deren zubereitungsmethode. ATE116540T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP61237027A JPH0725689B2 (ja) 1986-10-07 1986-10-07 顆粒球コロニ−刺激因子を含有する徐放性製剤

Publications (1)

Publication Number Publication Date
ATE116540T1 true ATE116540T1 (de) 1995-01-15

Family

ID=17009307

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87114584T ATE116540T1 (de) 1986-10-07 1987-10-06 Teilchenzubereitung mit verzögerter wirkstoffabgabe und deren zubereitungsmethode.

Country Status (10)

Country Link
US (1) US4853226A (de)
EP (1) EP0263490B1 (de)
JP (1) JPH0725689B2 (de)
KR (1) KR930007247B1 (de)
AT (1) ATE116540T1 (de)
AU (1) AU608250B2 (de)
CA (1) CA1315200C (de)
DE (1) DE3750943T2 (de)
ES (1) ES2068810T3 (de)
GR (1) GR3015485T3 (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US5129877A (en) * 1988-04-29 1992-07-14 University Of Georgia Research Foundation, Inc. Receptor-mediated delivery system
JP2827287B2 (ja) * 1988-07-05 1998-11-25 武田薬品工業株式会社 水溶性薬物含有徐放型マイクロカプセル
US5271945A (en) * 1988-07-05 1993-12-21 Takeda Chemical Industries, Ltd. Sustained release microcapsule for water soluble drug
US5041292A (en) * 1988-08-31 1991-08-20 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
JPH02212436A (ja) * 1989-02-14 1990-08-23 Japan Atom Energy Res Inst 徐放性基剤
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
EP0423484B1 (de) * 1989-10-16 1993-11-03 PCD-Polymere Gesellschaft m.b.H. Pressling mit retardierter Wirkstofffreisetzung
AT397345B (de) * 1990-04-04 1994-03-25 Chemiefaser Lenzing Ag Pharmazeutisches präparat mit verzögerter wirkstofffreisetzung auf basis von hemicellulosen
EP0459516A1 (de) * 1990-06-01 1991-12-04 Kirin-Amgen, Inc. Orale Arzneimittelformen von biologisch aktiven Eiweisstoffen
JP3249147B2 (ja) * 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
CA2061703C (en) * 1992-02-20 2002-07-02 Rudolf E. Falk Formulations containing hyaluronic acid
US5910489A (en) * 1990-09-18 1999-06-08 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
US5990096A (en) * 1990-09-18 1999-11-23 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US5824658A (en) * 1990-09-18 1998-10-20 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
US5639738A (en) * 1992-02-20 1997-06-17 Hyal Pharmaceutical Corporation Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs
ZA918168B (en) * 1990-10-16 1993-04-14 Takeda Chemical Industries Ltd Prolonged release preparation and polymers thereof.
IT1247472B (it) * 1991-05-31 1994-12-17 Fidia Spa Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.
US6022866A (en) * 1991-07-03 2000-02-08 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US5977088A (en) * 1991-07-03 1999-11-02 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US5792753A (en) * 1991-07-03 1998-08-11 Hyal Pharmaceutical Corporation Compositions comprising hyaluronic acid and prostaglandin-synthesis-inhibiting drugs
WO1994007505A1 (en) * 1991-07-03 1994-04-14 Norpharmco Inc. Use of hyaluronic acid and forms to prevent arterial restenosis
US5990095A (en) * 1991-07-03 1999-11-23 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US6103704A (en) * 1991-07-03 2000-08-15 Hyal Pharmaceutical Corporation Therapeutic methods using hyaluronic acid
US5817644A (en) * 1991-07-03 1998-10-06 Hyal Pharmaceutical Corporation Targeting of dosages of medicine and therapeutic agents
US6218373B1 (en) 1992-02-20 2001-04-17 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US5942498A (en) * 1992-02-20 1999-08-24 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US5767106A (en) * 1992-02-21 1998-06-16 Hyal Pharmaceutical Corporation Treatment of disease and conditions associated with macrophage infiltration
JP2651320B2 (ja) * 1992-07-16 1997-09-10 田辺製薬株式会社 徐放性マイクロスフェア製剤の製造方法
EP0595030A3 (de) * 1992-10-01 1995-06-07 Tanabe Seiyaku Co Mehrkern-Mikrosphären mit verzögerter Wirkstoffabgabe und Verfahren zu deren Herstellung.
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
JP3390477B2 (ja) * 1993-01-25 2003-03-24 生化学工業株式会社 薬剤組成物及びその製造法
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5478355A (en) * 1993-03-18 1995-12-26 United States Surgical Corporation Method for improving the in vivo strength retention of a bioabsorbable implantable medical device and resulting medical device
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
HU225496B1 (en) * 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
IL110787A0 (en) * 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
EP2283821A1 (de) * 1993-11-19 2011-02-16 Alkermes, Inc. Herstellung biodegradierbarer Mikroteilchen, die ein biologisch aktives Mittel enthalten
AUPM572294A0 (en) * 1994-05-18 1994-06-09 Vaccine Technologies Pty. Ltd. Delivery vehicle for bioactive molecule
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
DE69608122T3 (de) 1995-11-09 2011-06-16 Microbiological Research Authority Camr, Salisbury Mikroverkapselte dna zur impfung und gentherapie
KR100236771B1 (ko) * 1997-04-01 2000-02-01 성재갑 히아루론산을 이용한 약물의 서방성 미세입자 제형
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US20020182258A1 (en) * 1997-01-22 2002-12-05 Zycos Inc., A Delaware Corporation Microparticles for delivery of nucleic acid
WO1999028454A1 (en) * 1997-11-28 1999-06-10 Roche Diagnostics Gmbh An active hedgehog-protein-mutant, a process for its preparation and its use for pharmaceutical purposes
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
FR2778847A1 (fr) * 1998-05-20 1999-11-26 Jean Pierre Perraud Implant injectable en sous gingival resorbable, constitue de microspheres a liberation prolongee et chargees en principes actifs et en suspension dans un gel vecteur
ES2253851T3 (es) 1998-08-07 2006-06-01 Curis, Inc. Composicion farmaceutica estable de proteinas hedgehog y uso de la misma.
KR100845769B1 (ko) * 1999-02-03 2008-07-11 파우더젝트 리서치 리미티드 하이드로겔 입자 제제
US6204308B1 (en) 1999-03-01 2001-03-20 Novartis Ag Organic compounds
JP5031144B2 (ja) * 1999-03-25 2012-09-19 メタボリックス，インコーポレイテッド ポリヒドロキシアルカノエートポリマーの医療デバイスおよび医療適用
US7651703B2 (en) 1999-10-15 2010-01-26 Genentech, Inc. Injection vehicle for polymer-based formulations
US7582311B1 (en) * 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
CN1537018A (zh) 2001-05-23 2004-10-13 田边制药株式会社 一种用于软骨疾病再生治疗的组合物
EP1389468A4 (de) 2001-05-23 2007-01-10 Tanabe Seiyaku Co Zusammensetzungen zur förderung der knochenfrakturheilung
WO2003000156A1 (en) 2001-06-22 2003-01-03 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
US20050191361A1 (en) * 2001-08-03 2005-09-01 Powederject Research Ltd. Hydrogel particle formation
AU2003261723A1 (en) 2002-08-27 2004-03-19 Takeda Chemical Industries, Ltd. Cxcr4 antagonist and use thereof
US20040226620A1 (en) 2002-09-26 2004-11-18 Daniel Therriault Microcapillary networks
BR0314911A (pt) * 2002-10-22 2005-09-27 Japan Science & Tech Agency Inibidor de infecção pelo vìrus da dengue e anticorpo monoclonal
US7053125B2 (en) 2002-11-14 2006-05-30 The Board Of Trustees Of The University Of Illinois Controlled dispersion of colloidal suspension by comb polymers
ES2527857T3 (es) 2003-05-08 2015-01-30 Tepha, Inc. Tejidos y fibras médicas de polihidroxialcanoato
US7141617B2 (en) 2003-06-17 2006-11-28 The Board Of Trustees Of The University Of Illinois Directed assembly of three-dimensional structures with micron-scale features
US20050025809A1 (en) * 2003-07-08 2005-02-03 Tepha, Inc. Poly-4-hydroxybutyrate matrices for sustained drug delivery
JP2007503221A (ja) * 2003-08-22 2007-02-22 テファ， インコーポレイテッド ポリヒドロキシアルカノエート神経再生デバイス
US7867511B2 (en) 2004-01-23 2011-01-11 Travanti Pharma Inc. Abuse potential reduction in abusable substance dosage form
FI116625B (fi) * 2004-01-28 2006-01-13 Macrocrystal Oy Menetelmä proteiinien kiteyttämiseksi hiilihydraattirunkoisilla polymeereillä
US20050271726A1 (en) * 2004-06-02 2005-12-08 Albert Crum Immune enhancing compositions and methods of use thereof
PT1778305E (pt) * 2004-08-03 2010-07-27 Tepha Inc Suturas de poli-hidroxialcanoato que n†o se enrolam
ATE481088T1 (de) * 2005-01-28 2010-10-15 Tepha Inc Embolisierung unter verwendung von poly-4- hydroxybutyrat-partikeln
DE102006013531A1 (de) * 2006-03-24 2007-09-27 Lts Lohmann Therapie-Systeme Ag Polylactid-Nanopartikel
CA2662581C (en) * 2006-09-13 2018-01-30 Enhance Skin Products, Inc. Cosmetic composition for the treatment of skin and methods thereof
US7943683B2 (en) * 2006-12-01 2011-05-17 Tepha, Inc. Medical devices containing oriented films of poly-4-hydroxybutyrate and copolymers
WO2008075371A2 (en) 2006-12-21 2008-06-26 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for immunomodulation
US7956102B2 (en) 2007-04-09 2011-06-07 The Board Of Trustees Of The University Of Illinois Sol-gel inks
US7922939B2 (en) 2008-10-03 2011-04-12 The Board Of Trustees Of The University Of Illinois Metal nanoparticle inks
US8187500B2 (en) 2008-10-17 2012-05-29 The Board Of Trustees Of The University Of Illinois Biphasic inks
US9155780B2 (en) 2009-02-11 2015-10-13 Yeda Research And Development Co. Ltd. Short beta-defensin-derived peptides
BRPI1009663A2 (pt) 2009-06-14 2016-10-11 Biokine Therapeutics Ltd "método para elevação dos níveis plaquetários em um indivíduo com essa necessidade, método de inibição de hemorragia em um indivíduo que a necessite e composição farmacêutica"
EP2841084B1 (de) 2012-04-24 2018-05-30 Biokine Therapeutics Ltd. Cxcr4 antagonist peptid zur verwendung in der behandlung von lungenkrebs
EP3180040B1 (de) 2014-08-15 2020-05-13 Tepha, Inc. Selbsthaltendes chirurgisches nahtmaterial aus poly-4-hydroxybutyrat und copolymeren davon
US10626521B2 (en) 2014-12-11 2020-04-21 Tepha, Inc. Methods of manufacturing mesh sutures from poly-4-hydroxybutyrate and copolymers thereof
WO2016094669A1 (en) 2014-12-11 2016-06-16 Tepha, Inc. Methods of orienting multifilament yarn and monofilaments of poly-4-hydroxybutyrate and copolymers thereof
US10786547B2 (en) 2015-07-16 2020-09-29 Biokine Therapeutics Ltd. Compositions, articles of manufacture and methods for treating cancer
KR102033920B1 (ko) 2016-02-23 2019-10-18 바이오라인알엑스 리미티드 급성 골수성 백혈병을 치료하는 방법
WO2018138267A1 (en) 2017-01-27 2018-08-02 Cinfa Biotech S.L. Method for determining the efficacy of a g-csf containing composition
US11389844B2 (en) 2018-03-20 2022-07-19 Verde Environmental Technologies, Inc. Blister pack disposal system
CN115248141A (zh) * 2021-04-28 2022-10-28 北京泰德制药股份有限公司 一种制备缓释药物组合物检测样品的方法
CN115970051B (zh) * 2023-02-09 2023-08-29 辽宁天贺生物科技研究院有限公司 可降解组织工程填充材料及其制备方法和用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3045135A1 (de) * 1980-11-29 1982-06-09 Sandoz-Patent-GmbH, 7850 Lörrach Pharmazeutische kompositionen enthaltende bioabbaubare polymere
JPS57120518A (en) * 1981-01-19 1982-07-27 Tanabe Seiyaku Co Ltd Preparation of microcapsule
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0092918B1 (de) * 1982-04-22 1988-10-19 Imperial Chemical Industries Plc Mittel mit verzögerter Freigabe
JPS5933214A (ja) * 1982-08-19 1984-02-23 Mitsui Toatsu Chem Inc 微小球に製剤された制ガン剤の製造方法
CH660488A5 (en) * 1982-12-17 1987-04-30 Sandoz Ag (Co)oligomeric hydroxycarboxylic acid derivatives, the preparation thereof, and the use thereof in pharmaceutical compositions
EP0140255B1 (de) * 1983-10-14 1991-05-15 Sumitomo Pharmaceuticals Company, Limited Injektionen mit verzögerter Abgabe
EP0139286B1 (de) * 1983-10-14 1991-08-21 Sumitomo Pharmaceuticals Company, Limited Verlängerte Präparate mit verzögerter Abgabe
JPS60112713A (ja) * 1983-11-21 1985-06-19 Sumitomo Chem Co Ltd 有用な徐放性注射剤
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
GB8416234D0 (en) * 1984-06-26 1984-08-01 Ici Plc Biodegradable amphipathic copolymers
JPS61227526A (ja) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
JPS6163613A (ja) * 1984-09-04 1986-04-01 Mitsui Toatsu Chem Inc 顆粒状に調整された徐放性製剤
JPS6165816A (ja) * 1984-09-10 1986-04-04 Mitsui Toatsu Chem Inc 顆粒状の徐放性製剤
DE3686275T2 (de) * 1985-01-11 1993-03-18 Teijin Ltd Praeparate mit verzoegerter freisetzung.
ATE65798T1 (de) * 1985-02-08 1991-08-15 Chugai Pharmaceutical Co Ltd Menschlicher granuloxcyt-koloniestimulierungsfaktor.
JPS61277612A (ja) * 1985-05-31 1986-12-08 Kiyoshi Morikawa 接種用徐放性組成物
DE3681551D1 (de) * 1985-09-30 1991-10-24 Chugai Pharmaceutical Co Ltd Menschlicher granulozyten-colony stimulierender faktor.
JPH0725688B2 (ja) * 1986-03-31 1995-03-22 住友製薬株式会社 Ｃｓｆ徐放性製剤

Also Published As

Publication number Publication date
AU7940487A (en) 1988-04-14
EP0263490A3 (en) 1990-05-16
US4853226A (en) 1989-08-01
ES2068810T3 (es) 1995-05-01
DE3750943T2 (de) 1995-05-11
EP0263490A2 (de) 1988-04-13
GR3015485T3 (en) 1995-06-30
CA1315200C (en) 1993-03-30
DE3750943D1 (de) 1995-02-16
KR930007247B1 (ko) 1993-08-04
AU608250B2 (en) 1991-03-28
JPH0725689B2 (ja) 1995-03-22
JPS6391325A (ja) 1988-04-22
EP0263490B1 (de) 1995-01-04
KR880004802A (ko) 1988-06-27

Similar Documents

Publication Publication Date Title
ATE116540T1 (de) Teilchenzubereitung mit verzögerter wirkstoffabgabe und deren zubereitungsmethode.
US4767628B1 (de)
US5081156A (en) Sustained-release preparation
HUT55220A (en) Process for producing pharmaceutical composition suitable for systemic administration through the skin and comprising deprenyl as active ingredient
IL78826A (en) Precursor composition for the preparation of a biodegradable implant for the sustained release of an active material and such implants prepared therefrom
UA35569C2 (uk) Композиція для пролонгованого і контрольованого вивільнення пептидної лікарської речовини і спосіб її одержання, спосіб приготування суспензії, що призначена для парентерального введення
AU576365B2 (en) Collagen and or fibrinogen as carrier of drugs for their introduction into cellular lesion areas
HK64893A (en) Stable pharmaceutical preparation containing granulocyte colony stimulating factor and process for producing the same
RU93036959A (ru) Свободно растворимый лекарственный препарат с замедленным действием биологически активных веществ, назначенный для приема внутрь, способ его производства
NO930743L (no) Systemer for pulserende en-gang-om-dagen-avgivelse for minocyklin
PT82949A (de) Feste arzneimittelformen zur peroralen annendung enthalted 9-deoxo-11-deoxy-9,11-<imino<2-(2-methoxyethoxy)ethyliden>-oxy>-(9s)-erythromycin und verfahren zu ihrer herstellung
DE68928034D1 (de) Protein mit zeitverabreichung
HUT60436A (en) Process for producing pharmaceutical composition active mainly on thrombo-embolitic conditions of circulatory system and heart
HUT59319A (en) Pharmaceutical compositions with controlled release of active ingredient and process for producing same
ZA884622B (en) Pharmaceutical compositions in the form of pellets with enzymatically controlled release of the pharmaceutical,substance
ATE87467T1 (de) Pharmazeutische zubereitung.
AU566228B2 (en) Compressed hydroxybutryic acid polymer retarded release vehicle
NO870104D0 (no) Farmasoeytisk preparat med vedvarende frigivelse av den aktive komponenten og fremgangsmaate for fremstilling derav.
SE8600496L (sv) Farmaceutiska kompositioner innehallande 9,10-dihydroergotalkaloider
FI880210L (fi) Menetelmä valmistaa peroraalista stabiloitua, tehoainetta hidastetusti ja kontrolloidusti vapauttavaa, lääkevalmistetta
Schröder [9] Crystallized carbohydrate spheres for slow release and targeting
HUT48880A (en) Insecticides and acaricides comprising new n-benzoyl-n'-thienyl urea derivative as active ingredient and process for producing the active ingredients
DE3878154D1 (de) Oral anzuwendende arzneiform zur einmal taeglichen behandlung der hypertonie mit diltiazemhydrochlorid.
SU1600502A1 (ru) Способ приготовления эритроцитарного диагностикума для индикации лекарственной аллергии к антибиотикам
BG44228A1 (en) Composition and method for preparing of biologically active means with antiseborrea action

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time